Acute myeloid leukemia, or AML, is a rare and aggressive cancer that can affect people of all ages. Kiran Vanaja, an ...

Acute myeloid leukemia (AML) is a particularly aggressive form of blood cancer that usually progresses rapidly if swift and intensive treatment is not applied. Although the disease can often be ...

KOMZIFTI FDA launch, early revenue, payer coverage, AML expansion plans, cash runway and 2026 outlook—read now.

Panelists discuss how fitness assessment has evolved beyond traditional age cutoffs to incorporate comprehensive geriatric assessments, frailty measures, and individualized evaluations, while ...

A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving acute myeloid leukemia (AML), an aggressive blood cancer affecting the bone ...

Panelists discuss how oral azacitidine plus venetoclax represents a transformative advance toward completely oral regimens that could dramatically improve quality of life and accessibility, though ...

The University of Warwick, which is setting up the Registry, plans to collect data for analysis from 500 AML patients at sites in 30 large metropolitan NHS hospitals across the UK by the end of this ...

Investors are monitoring the Miami Cancer Institute Immunotherapies Summit, where Sellas' scientific advisor, Guenther Koehne, is set to deliver opening remarks. ・The Phase 3 Regal trial evaluating ...

Anthracycline and cytarabine chemotherapy has been the backbone of induction chemotherapy for AML for more than 50 years. Advances in our understanding of leukemia biology and the development of ...

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more ...